PDE5 Inhibitors and Novel Soluble Guanylate Cyclase Activators in the Treatment of Lower Urinary Tract Symptoms—Clinical Implications and Mechanistic Concepts

Workshop 37

Workshop Schedule

11:30

Marcus John Drake

11:50

Lori A Birder

12:10

Anthony John Kanai

12:30

Christopher Henry Fry

12:50

Anthony John Kanai
Marcus John Drake
Lori A Birder
Christopher Henry Fry

Aims & Objectives

Advanced
90 minutes
Neurourology
Basic Science / Translational
Urothelial signalling Afferent sensitisation Bladder relaxation
Urology, Urogynaecology, Basic Science
PDE5 inhibitors (e.g., tadalafil, sildenafil) may be used to treat lower urinary tract symptoms (LUTS). They are proposed to work by increasing protein kinase G (PKG) signalling via nitric oxide (NO•)-induced activation of soluble guanylate cyclase (sGC). This alters the functional behaviour of targets including: urothelial cells, afferent and efferent nerves, as well as detrusor smooth muscle, by mechanisms incompletely understood. sGC activators (e.g., BAY-582667) also increase PKG activity but, crucially, can do so in the absence of NO• which can occur if nitrergic nerves are damaged. Our aims are to discuss the cellular targets, mechanisms of actions and therapeutic relevance of PDE5 inhibitors and sGC activators to treat LUTS.